We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current OBIPF market cap is 0. The company's latest EPS is TWD and P/E is N/A.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| TWD (TWD) | TWD (TWD) | TWD (TWD) | TWD (TWD) | TWD (TWD) | |
| Total Revenue | 5.59M | 140.89M | 18.77M | 4.71M | 41.55M |
| Operating Income | -1.57B | -1.46B | -1.71B | -2.12B | -2.25B |
| Net Income | -1.41B | -1.38B | -1.53B | -1.61B | -1.05B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| TWD (TWD) | TWD (TWD) | TWD (TWD) | TWD (TWD) | TWD (TWD) | |
| Total Assets | 6.49B | 5.34B | 4.49B | 6.63B | 5.6B |
| Total Liabilities | 564.28M | 502.09M | 615.95M | 497.57M | 650.45M |
| Total Equity | 5.92B | 4.84B | 3.87B | 6.14B | 4.95B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| TWD (TWD) | TWD (TWD) | TWD (TWD) | TWD (TWD) | TWD (TWD) | |
| Operating | -1.12B | -1.61B | -1.06B | -1.62B | -1.65B |
| Investing | -78.71M | -195.9M | 82.68M | -169.89M | -2.8B |
| Financing | 1.89B | 283.09M | 163.75M | 4.01B | 607.07M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 228.78M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | OBI Pharma Inc (PK) |
| Address |
6f., no. 508, sec. 7, zhongxiao e. rd taipei city |
| Website | https://www.obipharma.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
